A transcription factor is the target of propranolol treatment in infantile ...

The efficacy of propranolol was independent of its β-AR blocker activity and was attributable to the direct targeting of the transcription ...

Propranolol is a nonselective β-adrenergic receptor (AR) blocker that has been the first-line therapy for problematic infantile hemangioma ...

A transcription factor is the target of propranolol treatment in infantile ...

The efficacy of propranolol was independent of its β-AR blocker activity and was attributable to the direct targeting of the transcription factor SOX18, ...

A transcription factor is the target of propranolol treatment in infantile ...

A transcription factor is the target of propranolol treatment in infantile hemangioma · Journal of Clinical Investigation, February 2022 · 10.1172/jci156863.

A transcription factor is the target of propranolol treatment in infantile ...

A transcription factor is the target of propranolol treatment in infantile hemangioma. Citation metadata. Authors: Sandra Schrenk and Elisa Boscolo. Date: Feb ...

R-propranolol is a small molecule inhibitor of the SOX18 ... - eLife

Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma.

Infantile hemangioma: the common and enigmatic vascular tumor - JCI

Propranolol targets the endothelial transcription factor SOX18 to inhibit vasculogenesis in IH. Options: View larger image (or click on image) ...

Identification of putative biomarkers for Infantile Hemangiomas and ...

Propranolol is a non-selective -adrenergic receptor antagonist originally used to treat high blood pressure that has been re-purposed for ...

Infantile hemangioma: the common and enigmatic vascular tumor - JCI

Propranolol was serendipitously discovered to be an effective treatment for IH in a landmark study by Léauté-Labrèze and colleagues. Two infants ...

R-propranolol is a small molecule inhibitor of the SOX18 ...

R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma. Overman J 1 ,.

Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to ...

This work uncovers the role of the LIN28B/let-7 switch in IH pathogenesis and provides a novel mechanism by which propranolol induces IH ...

Propranolol exhibits activity against hemangiomas independent of ...

A fortuitous clinical observation was made in an infant who received propranolol for cardiac disease, and regression of a hemangioma of infancy was noted.

An endothelial SOX18-mevalonate pathway axis enables ... - bioRxiv

Propranolol is the mainstay of treatment for IH. It inhibits hemangioma vessel formation via a β-adrenergic receptor independent off-target ...

R-propranolol is a small molecule inhibitor of the SOX18 ...

Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma.

Propranolol in the Treatment of Infantile Hemangiomas | CCID

Upregulation of angiogenesis transcription factors like hypoxia-inducible factor (HIF-1α) and vascular endothelial growth factor-A (VEGF-A) ...

CLINICAL ANALYSIS OF 403 PATIENTS | Terzi | SANAMED

ORAL TOPICAL TIMOLOL MALEAT OR ORAL PROPRANOLOL TREATMENT FOR INFANTILE ... A transcription factor is the target of propranolol treatment in infantile hemangioma.

Propranolol targets the endothelial transcription factor SOX18 to...

Propranolol targets the endothelial transcription factor SOX18 to inhibit vasculogenesis in IH. (A) The R(+) enantiomers of propranolol and atenolol and the ...

R-propranolol is a small molecule inhibitor of the SOX18 ... - OUCI

Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma. Despite the clinical benefit of ...

Cited By (CrossRef) - Spandidos Publications

... children with infantile hemangiomas on systemic propranolol treatment ... A transcription factor is the target of propranolol treatment in infantile hemangioma

Propranolol Therapy in Infantile Hemangioma: It Is Not Just

Propranolol, a nonselective β-adrenergic receptor antagonist, is approved by the U.S. Food and Drug Administration to treat problematic infantile hemangiomas, ...